Accessibility Menu
Medicenna Therapeutics logo

Medicenna Therapeutics

(TSX) MDNA

Current PriceCA$0.45
Market CapCA$30.59M
Since IPO (2017)-84%
5 Year-90%
1 Year-51%
1 Month-28%

Medicenna Therapeutics Financials at a Glance

Market Cap

CA$30.59M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$12.99M

EPS (TTM)

-CA$0.16

P/E Ratio

-2.86

Dividend

CA$0.00

Beta (Volatility)

1.07 (Average)

Price

CA$0.45

Volume

85,416

Open

CA$0.47

Previous Close

CA$0.45

Daily Range

CA$0.44 - CA$0.48

52-Week Range

CA$0.41 - CA$1.97

Estimated Earnings Date

Jun 25, 2026

MDNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicenna Therapeutics

Industry

Biotechnology

Employees

18

CEO

Fahar Merchant, PhD

Headquarters

Toronto, ON M4W 3E2, CA

MDNA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-110%

Return on Capital

-3%

Return on Assets

-99%

Earnings Yield

-34.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$30.59M

Shares Outstanding

68.74M

Volume

85.42K

Avg. Volume

115.91K

Financials (TTM)

Gross Profit

-CA$55.00K

Operating Income

-CA$21.63M

EBITDA

-CA$12.98M

Operating Cash Flow

-CA$16.49M

Capital Expenditure

-CA$33.00K

Free Cash Flow

-CA$16.53M

Cash & ST Invst.

CA$24.84M

Total Debt

CA$168.00K

Medicenna Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$16.00K

+23.8%

Gross Margin

0.00%

N/A

Market Cap

CA$30.59M

N/A

Market Cap/Employee

CA$1.91M

N/A

Employees

16

N/A

Net Income

-CA$4.36M

+15.9%

EBITDA

-CA$5.60M

-9.8%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Net Cash

CA$10.41M

-65.1%

Accounts Receivable

CA$1.47M

+2.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$140.00K

+4.5%

Short Term Debt

CA$65.00K

-18.8%

Return on Assets

-99.41%

N/A

Return on Invested Capital

-2.71%

N/A

Free Cash Flow

CA$0.00

+100.0%

Operating Cash Flow

-CA$4.97M

-39.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MIR.VMedMira Inc.
CA$0.06+9.09%
SVA.TOSernova Corp.
CA$0.15-3.23%
COV.VCovalon Technologies Ltd.
CA$2.10-2.33%
ZEN.VZentek Ltd.
CA$0.70-4.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
KEELKeel Infrastructure
$5.13-0.13%
NIONio
$5.36-0.06%
SNAPSnap
$5.76-0.05%
SGOViShares Trust - iShares 0-3 Month Treasury Bond ETF
$100.45+0.00%

Questions About MDNA

What is the current price of Medicenna Therapeutics?

Medicenna Therapeutics is trading at CA$0.45 per share.

What is the 52-week range for Medicenna Therapeutics?

Over the past 52 weeks, Medicenna Therapeutics has traded between CA$0.41 and CA$1.97.

How much debt does Medicenna Therapeutics have?

As of the most recent reporting period, Medicenna Therapeutics reported total debt of CA$135.00K.

How much cash does Medicenna Therapeutics have on hand?

Medicenna Therapeutics reported CA$10.61M in cash and cash equivalents in its most recent financial results.

What is Medicenna Therapeutics’s dividend yield?

Medicenna Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.